Genocea Biosciences Inc. | Mutual Funds
Mutual Funds that own Genocea Biosciences Inc.
Vanguard Total Stock Market Index Fund
1,225,285
1.42%
0
0%
07/31/2018
Vanguard Extended Market Index Fund
751,470
0.87%
0
0%
07/31/2018
CREF Stock Account
243,213
0.28%
159,800
0%
03/31/2018
Fidelity Spartan Small Cap Index Fund
166,761
0.19%
114,492
0%
04/30/2018
Fidelity Spartan Extended Market Index Fund
157,873
0.18%
0
0%
07/31/2018
Vanguard Institutional Total Stock Market Index Fund
129,073
0.15%
0
0%
07/31/2018
AXA 2000 Managed Volatility Portfolio
116,872
0.14%
75,605
0%
03/31/2018
Fidelity Spartan Total Market Index Fund
59,471
0.07%
0
0%
07/31/2018
APO Medical Opportunities Institutionell
53,358
0.06%
53,358
0.02%
06/29/2018
TIAA-CREF Small Cap Blend Index Fund
33,811
0.04%
0
0%
05/31/2018
| Address |
Cambridge Discovery Park
Cambridge Massachusetts 02140
United States
|
|
Employees
|
- |
| Website |
http://www.genocea.com |
| Updated |
07/08/2019 |
| Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-003, an investigational immunotherapy for the treatment of genital herpes; and GEN-009, a neoantigen cancer vaccine. |
